JPS58192831A - 水晶体上皮細胞に対するモノクローナル抗体およびその製造方法 - Google Patents
水晶体上皮細胞に対するモノクローナル抗体およびその製造方法Info
- Publication number
- JPS58192831A JPS58192831A JP58034699A JP3469983A JPS58192831A JP S58192831 A JPS58192831 A JP S58192831A JP 58034699 A JP58034699 A JP 58034699A JP 3469983 A JP3469983 A JP 3469983A JP S58192831 A JPS58192831 A JP S58192831A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- lens epithelial
- antibody
- lens
- epithelial cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title claims description 5
- 210000004027 cell Anatomy 0.000 claims description 42
- 210000001542 lens epithelial cell Anatomy 0.000 claims description 35
- 230000004927 fusion Effects 0.000 claims description 4
- 230000016784 immunoglobulin production Effects 0.000 claims description 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 description 19
- 238000000034 method Methods 0.000 description 13
- 210000000695 crystalline len Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 210000002159 anterior chamber Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000008516 Capsule Opacification Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010036346 Posterior capsule opacification Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003644 lens cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000007446 Hip Dislocation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001007419 Homo sapiens Lens epithelial cell protein LEP503 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 229910017586 La2S3 Inorganic materials 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 210000003293 antilymphocyte serum Anatomy 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002683 hand surgery Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 102000055233 human LENEP Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/355,081 US4432751A (en) | 1982-03-05 | 1982-03-05 | Monoclonal antibodies against lens epithelial cells and preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
| US355081 | 1982-03-05 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4187160A Division JPH0751063B2 (ja) | 1982-03-05 | 1992-07-14 | 水晶体上皮細胞に対する抗体を産生するセルライン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58192831A true JPS58192831A (ja) | 1983-11-10 |
| JPH0537B2 JPH0537B2 (enExample) | 1993-01-05 |
Family
ID=23396159
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58034699A Granted JPS58192831A (ja) | 1982-03-05 | 1983-03-04 | 水晶体上皮細胞に対するモノクローナル抗体およびその製造方法 |
| JP4187160A Expired - Lifetime JPH0751063B2 (ja) | 1982-03-05 | 1992-07-14 | 水晶体上皮細胞に対する抗体を産生するセルライン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4187160A Expired - Lifetime JPH0751063B2 (ja) | 1982-03-05 | 1992-07-14 | 水晶体上皮細胞に対する抗体を産生するセルライン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4432751A (enExample) |
| EP (1) | EP0088606B1 (enExample) |
| JP (2) | JPS58192831A (enExample) |
| CA (1) | CA1209500A (enExample) |
| DE (1) | DE3372785D1 (enExample) |
| DK (1) | DK160562C (enExample) |
| GR (1) | GR77941B (enExample) |
| IE (1) | IE54702B1 (enExample) |
| IL (1) | IL69715A (enExample) |
| ZA (1) | ZA831168B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63211239A (ja) * | 1986-11-04 | 1988-09-02 | ベイラー カレッジ オブ メディスン | 白内障防止用組成物 |
| US4977968A (en) * | 1988-08-03 | 1990-12-18 | Kraemer Wilhelm L | Cleaning device for weighing machines, in particular combination weighing machines |
| JPH03501806A (ja) * | 1988-06-08 | 1991-04-25 | ベイラー カレッジ オブ メディスン | 水晶体上皮細胞に対するモノクローナル抗体及びのう外摘出後の残遺水晶体上皮細胞の増殖抑制方法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202252A (en) * | 1982-03-05 | 1993-04-13 | Houston Biotechnology Inc. | Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
| EP0256344B1 (de) * | 1986-08-18 | 1992-04-22 | Wolfgang G.K. Dr. Müller-Lierheim | Kontaktlinse |
| US5055291A (en) * | 1986-11-04 | 1991-10-08 | Baylor College Of Medicine | Compositions for preventing secondary cataracts |
| US4871350A (en) * | 1986-11-04 | 1989-10-03 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
| US5616122A (en) * | 1986-11-04 | 1997-04-01 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
| US4918165A (en) * | 1987-07-16 | 1990-04-17 | Ophthalmic Research Corporation | Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction |
| US4966577A (en) * | 1988-03-16 | 1990-10-30 | Allergan, Inc. | Prevention of lens-related tissue growth in the eye |
| US4909784A (en) * | 1988-03-25 | 1990-03-20 | Seymour Dubroff | Method for preventing clouding of posterior capsule after extracapsular cataract eye surgery |
| US5627162A (en) * | 1990-01-11 | 1997-05-06 | Gwon; Arlene E. | Methods and means for control of proliferation of remnant cells following surgery |
| JPH0555847U (ja) * | 1992-01-13 | 1993-07-27 | 三菱農機株式会社 | 脱穀機の受網目詰まり防止装置 |
| US5375611A (en) * | 1993-01-26 | 1994-12-27 | Pharmacia Ab | Method for preventing secondary cataract |
| US5876438A (en) * | 1993-08-02 | 1999-03-02 | Houston Biotechnology Incorporated | Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract |
| US5620013A (en) * | 1994-10-21 | 1997-04-15 | American Cyanamid Company | Method for destroying residual lens epithelial cells |
| CA2187482A1 (en) * | 1995-10-13 | 1997-04-14 | Eri Inoue | Pharmaceutical composition |
| US6106554A (en) * | 1999-02-25 | 2000-08-22 | Bausch & Lomb Surgical, Inc. | Intraocular lens implants for the prevention of secondary cataracts |
| US6454802B1 (en) | 2000-08-21 | 2002-09-24 | Bausch & Lomb Incorporated | Intraocular lens implant for the prevention of secondary cataracts |
| US6945971B1 (en) * | 2004-07-19 | 2005-09-20 | Gwon Arlene E | Controlled ocular lens regeneration |
| US7252662B2 (en) * | 2004-11-02 | 2007-08-07 | Lenticular Research Group Llc | Apparatus and processes for preventing or delaying one or more symptoms of presbyopia |
| AU2006213997A1 (en) | 2005-02-19 | 2006-08-24 | Lenticular Research Group Llc | Apparatus and processes for preventing or delaying onset or progression of age-related cataract |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307082A (en) * | 1979-07-10 | 1981-12-22 | New York University | Method for the extraction of a factor that mediates contact inhibition of cell growth |
| US4342828A (en) * | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4349528A (en) * | 1979-11-21 | 1982-09-14 | The Wistar Institute | Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen |
-
1982
- 1982-03-05 US US06/355,081 patent/US4432751A/en not_active Expired - Lifetime
-
1983
- 1983-02-22 ZA ZA831168A patent/ZA831168B/xx unknown
- 1983-02-24 DK DK084783A patent/DK160562C/da not_active IP Right Cessation
- 1983-03-04 EP EP83301176A patent/EP0088606B1/en not_active Expired
- 1983-03-04 GR GR70670A patent/GR77941B/el unknown
- 1983-03-04 DE DE8383301176T patent/DE3372785D1/de not_active Expired
- 1983-03-04 JP JP58034699A patent/JPS58192831A/ja active Granted
- 1983-03-04 IE IE467/83A patent/IE54702B1/en not_active IP Right Cessation
- 1983-03-04 CA CA000422956A patent/CA1209500A/en not_active Expired
- 1983-09-13 IL IL69715A patent/IL69715A/xx not_active IP Right Cessation
-
1992
- 1992-07-14 JP JP4187160A patent/JPH0751063B2/ja not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63211239A (ja) * | 1986-11-04 | 1988-09-02 | ベイラー カレッジ オブ メディスン | 白内障防止用組成物 |
| JPH03501806A (ja) * | 1988-06-08 | 1991-04-25 | ベイラー カレッジ オブ メディスン | 水晶体上皮細胞に対するモノクローナル抗体及びのう外摘出後の残遺水晶体上皮細胞の増殖抑制方法 |
| US4977968A (en) * | 1988-08-03 | 1990-12-18 | Kraemer Wilhelm L | Cleaning device for weighing machines, in particular combination weighing machines |
Also Published As
| Publication number | Publication date |
|---|---|
| IE830467L (en) | 1983-09-05 |
| DK160562B (da) | 1991-03-25 |
| IE54702B1 (en) | 1990-01-17 |
| CA1209500A (en) | 1986-08-12 |
| ZA831168B (en) | 1983-11-30 |
| EP0088606B1 (en) | 1987-07-29 |
| DK84783A (da) | 1983-09-06 |
| JPH05184358A (ja) | 1993-07-27 |
| DK84783D0 (da) | 1983-02-24 |
| EP0088606A2 (en) | 1983-09-14 |
| DE3372785D1 (en) | 1987-09-03 |
| EP0088606A3 (en) | 1984-03-28 |
| IL69715A (en) | 1988-06-30 |
| DK160562C (da) | 1991-09-02 |
| JPH0537B2 (enExample) | 1993-01-05 |
| JPH0751063B2 (ja) | 1995-06-05 |
| US4432751A (en) | 1984-02-21 |
| GR77941B (enExample) | 1984-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58192831A (ja) | 水晶体上皮細胞に対するモノクローナル抗体およびその製造方法 | |
| Grobstein | Inductive tissue interaction in development | |
| Coulombre et al. | The skeleton of the eye: I. Conjunctival papillae and scleral ossicles | |
| Zhang et al. | Transplantation of GMP-grade human iPSC-derived retinal pigment epithelial cells in rodent model: the first pre-clinical study for safety and efficacy in China | |
| MXPA04004309A (es) | Celulas estromales derivadas de tejido adiposo para la reparacion de defectos corneales e intraorbitales y usos de las mismas. | |
| Espana et al. | Existence of corneal endothelial slow-cycling cells | |
| Thumann et al. | TRANSPLANTATION OF AUTOLOGOUS IRIS PIGMENT EPITHELIUM TO THE SUBRETINAL SPACE IN RABBITS1 | |
| Xian et al. | Dexamethasone provides effective immunosuppression for improved survival of retinal organoids after epiretinal transplantation | |
| Wartchow et al. | Insulin-producing cells from mesenchymal stromal cells: Protection against cognitive impairment in diabetic rats depends upon implant site | |
| Lucké | Characteristics of frog carcinoma in tissue culture | |
| Puck et al. | Cellular deposits on intraocular lenses | |
| Ho et al. | Tissue culture of retinal pigment epithelium following isolation with a gelatin matrix technique | |
| CN108210494B (zh) | Foxm1抑制剂fdi-6抗肝纤维化的应用 | |
| Ehrlich et al. | The effects of anti-cornea and anti-heart serum on cultured cells of rabbit cornea and other tissues | |
| Samelska et al. | The immunology of corneal limbal stem cells: The up-to-date approach to stem cell transplantation | |
| CN111836884A (zh) | 源自干细胞的泪腺组织的制作方法 | |
| Treffers | Corneal endothelial wound healing | |
| Hu et al. | A new isolation method of human lacrimal canaliculus epithelial stem cells by maintaining close association with their niche cells | |
| WO2024011449A1 (zh) | 视网膜色素上皮细胞在替代角膜内皮方面的应用 | |
| Okamoto et al. | Difference between dorsal and ventral iris in lens producing potency in normal lens regeneration is maintained after dissociation and reaggregation of cells from the adult newt, Cynops pyrrhogaster | |
| Reyer | Morphological evidence for lens differentiation from intra-ocular implants of lens epithelium in Ambystoma maculatum | |
| KR101645901B1 (ko) | 양막 슬라이드 지지체를 이용한 윤부줄기세포 배양방법 | |
| WO2004087897A1 (ja) | 水晶体細胞の作製方法、およびこの方法によって得られる水晶体細胞 | |
| Cuny et al. | Effect of bovine pituitary hormone preparations on newt lens regeneration in vitro: Stimulation by thyrotropin | |
| RU2157675C2 (ru) | Способ лечения заболеваний роговицы |